[go: up one dir, main page]

Hansen, 1998 - Google Patents

The aging pancreas, glucose tolerance and insulin action

Hansen, 1998

Document ID
6689336722229140956
Author
Hansen B
Publication year
Publication venue
INTERDISCIPLINARY TOPICS IN GERONTOLOGY

External Links

Snippet

As in many organs and systems, differentiating age-related impairment from early phases in the development of disease processes is challenging in the area of insulin secretion, insulin action and glucose homeostasis. The metabolism of all nutrients–carbohydrates, fats and …
Continue reading at books.google.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Similar Documents

Publication Publication Date Title
Caprio et al. Metabolic impact of obesity in childhood
DeFronzo From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus
Zierath et al. Insulin action in skeletal muscle from patients with NIDDM
Polonsky et al. Non-insulin-dependent diabetes mellitus—a genetically programmed failure of the beta cell to compensate for insulin resistance
Watkins et al. Diabetes and its management
Weyer et al. Metabolic factors contributing to increased resting metabolic rate and decreased insulin-induced thermogenesis during the development of type 2 diabetes.
AU2017380844B2 (en) Myostatin, activin or activin receptor antagonists for use in treating obesity and related conditions
DeFronzo et al. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake
Leong et al. Obesity and diabetes
Clocquet et al. Impaired insulin secretion and increased insulin sensitivity in familial maturity-onset diabetes of the young 4 (insulin promoter factor 1 gene).
O’Leary et al. Exercise-induced reversal of insulin resistance in obese elderly is associated with reduced visceral fat
AU645076B2 (en) Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
Flaim et al. Effects of thyroxine on protein turnover in rat skeletal muscle.
Del Toro-Equihua et al. Effect of an avocado oil-enhanced diet (Persea americana) on sucrose-induced insulin resistance in Wistar rats
Pandolfo Friedreich ataxia
Albu et al. Obesity and diabetes
Kim et al. Effect of dietary Platycodon grandiflorum on the improvement of insulin resistance in obese Zucker rats
Zhang et al. NPY modulates PYY function in the regulation of energy balance and glucose homeostasis
van Haeften Early disturbances in insulin secretion in the development of type 2 diabetes mellitus
Bauman The potential metabolic consequences of cerebral palsy: inferences from the general population and persons with spinal cord injury
Umpierrez et al. Ketosis-prone type 2 diabetes: effect of hyperglycemia on β-cell function and skeletal muscle insulin signaling
JP2010522332A (en) Method for monitoring drug efficacy in diabetic patients using an assay for 1,5-anhydro-D-glucitol
Arai et al. Effect of a novel palatinose-based liquid balanced formula (MHN-01) on glucose and lipid metabolism in male Sprague-Dawley rats after short-and long-term ingestion
Salonen et al. Role of childhood growth on the risk of metabolic syndrome in obese men and women
Reeds et al. Adipose tissue, hepatic, and skeletal muscle insulin sensitivity in extremely obese subjects with acanthosis nigricans